peptide guide FAQ

Discard it. Reconstituted dihexa left at room temperature for more than 2 hours has undergone measurable aggregation and oxidative degradation. The solution may still look clear and sterile, but peptide bioactivity has dropped significantly. There's no home test to confirm potency. And using degraded peptide in a research protocol introduces confounding variables that invalidate your results. The cost of replacing one vial is negligible compared to the cost of unreliable data across an entire study.

Assess whether the vial seal remained intact and whether ambient humidity exceeded 60%. If both conditions held. Sealed vial, dry environment. The peptide likely retained 85–90% potency, though some aggregation may have started. Refrigerate or freeze it immediately and use it within the next 30 days rather than storing it for the full 24-month window. If the seal was compromised or the environment was humid, the powder may have absorbed moisture, which accelerates degradation even after you return it to freezer storage. Consider this batch compromised for long-term studies where precision dosing matters.

Aliquot the unused solution into sterile single-use volumes (0.5–1.0 mL cryovials), label them with the reconstitution date, and freeze at −20°C immediately. Don't wait until day 27 to freeze leftovers. This extends usability to 3–6 months, but you'll accept 10–15% activity loss from the freeze-thaw process. Thaw one vial at a time in the refrigerator when needed and use it within 24 hours of thawing. Do not refreeze thawed aliquots. Discard any unused solution after 24 hours post-thaw.

This isn't experimental error. It's the peptide's homeostatic regulation. Doses above 10 nmol in rodent models consistently produce alertness rather than sedation, supporting the hypothesis that DSIP modulates sleep pressure bidirectionally. If a research protocol encounters this response, reduce the dose by 40–60% rather than increasing it. The therapeutic window for sleep promotion appears narrower than initially assumed, and exceeding it reveals DSIP's wake-promoting capacity.

The 2008 clinical trial found no significant weight loss with AOD-9604 at any dose (1mg, 5mg, or 10mg daily) after 12 weeks. If you're using a research-grade peptide and not seeing results, the compound may not produce the lipolytic effects observed in preclinical animal models when administered to humans. Wegovy's mechanism is distinct. It reduces caloric intake through appetite suppression rather than increasing fat oxidation. And has demonstrated consistent efficacy across multiple large-scale trials.

This is expected and reflects the difference between vascular clearance and tissue-level pharmacodynamics. Klow activates intracellular signaling cascades (AMPK phosphorylation, PGC-1α transcription) that persist well beyond the peptide's plasma presence. Once AMPK is activated, downstream metabolic effects continue for hours even after circulating peptide is cleared. If you're measuring mitochondrial DNA copy number or fatty acid oxidation markers, the relevant timeframe is 12–24 hours post-dose, not the 6–8 hour plasma half-life.

Extend dosing schedules without concern for tolerance. 12-week protocols show maintained efficacy. Store reconstituted DSIP at 2–8°C and use within 28 days once mixed with bacteriostatic water. Lyophilised powder remains stable at -20°C for 24–36 months, making long-term studies logistically feasible without mid-protocol peptide degradation. Track delta-wave percentage via polysomnography at weeks 0, 4, 8, and 12 to quantify architectural changes. Subjective sleep quality scores alone miss DSIP's primary mechanism.

Administer the missed dose as soon as you realize the lapse if fewer than 6 hours have passed since the scheduled time, then resume the regular schedule. If more than 6 hours have passed, skip the missed dose entirely and continue with the next scheduled administration. Doubling up disrupts steady-state kinetics and introduces concentration spikes that weren't part of your original protocol design. Missing a single dose in a 14-day study has minimal impact on cumulative tissue exposure, but missing consecutive doses resets the steady-state window and requires an additional 5–7 days to re-establish baseline tissue saturation.

Transitioning from a research peptide to a prescription medication requires formal medical evaluation. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Conditions that must be screened before initiating GLP-1 therapy. AOD-9604 does not affect GLP-1 receptors, so there's no pharmacological interaction, but starting Wegovy requires dose titration from 0.25mg weekly to avoid severe GI side effects.

Compounded semaglutide from FDA-registered 503B facilities costs $250–$500 per month compared to Wegovy's $1,300–$1,600 without insurance. The active molecule is identical, though the final formulation lacks FDA approval as a finished drug product. AOD-9604's lower price ($80–$150/month) reflects its research-only status. It is not a functional substitute for GLP-1 therapy.

Design the protocol to measure sleep architecture, not just total sleep time. DSIP's effects manifest in stage distribution (increased slow-wave, preserved REM), while melatonin primarily shifts circadian phase and Z-drugs suppress deep sleep while forcing sedation. Use EEG spectral analysis to quantify delta power (0.5–4 Hz) and sleep spindle density. These metrics differentiate DSIP's architecture-preserving profile from compounds that trade quality for duration. Include cognitive testing (reaction time, working memory) the morning after administration to capture next-day impairment differences.

A reconstituted vial stored at room temperature (20–25°C) for 12–16 hours loses 25–35% potency due to peptide bond hydrolysis and aggregation. It's not a total loss, but it's no longer the concentration stated on the label. If this happens early in a study, discard the vial and reconstitute fresh peptide to maintain dosing consistency. If it happens late in a chronic protocol, document the deviation and consider extending the study duration by 2–3 days to compensate for the reduced effective dose during that administration window.

AOD-9604 is not approved for human therapeutic use and cannot legally be marketed or prescribed for weight loss. If you're seeking a peptide-based approach outside prescription GLP-1 agonists, consult a licensed prescriber who can evaluate whether compounded semaglutide or other FDA-approved medications align with your metabolic profile. AOD-9604 remains classified as a research compound. Using it outside investigational settings carries regulatory and safety risks.

Explain that opening the container will compromise temperature control for a research biological material and offer to open it in a private screening area where you can immediately re-ice the container. Most officers will accept a visual inspection through the container's transparent lid or an exterior swab test without requiring full disassembly. If forced to open it, do so quickly, minimize air exchange, and replace gel packs or activate backup cooling immediately. Document the time the container was open. If it exceeds 10 minutes, the peptide may have experienced a measurable temperature spike.

Persistent cloudiness after two minutes of gentle swirling indicates either peptide aggregation or the presence of insoluble excipients. Do not use cloudy solutions. Aggregated peptides have unpredictable bioavailability and may trigger immune responses in cell culture or animal models. Filter the solution through a 0.22 µm sterile syringe filter as a diagnostic step: if cloudiness clears, the issue was particulate contamination; if it persists, the peptide itself has aggregated and the vial should be discarded.

Peptides below 95% purity contain meaningful levels of synthesis byproducts, truncated sequences, or deletion peptides that interfere with receptor binding and introduce variability across doses. A 92% purity result means 8% of the vial's mass is not KPV. That is not acceptable for reproducible research. Request a refund or replacement from a supplier offering ≥98% purity. For context, Real Peptides maintains a minimum 98% purity threshold across our entire peptide line, including KPV 5MG, verified by third-party HPLC.

State plainly: 'It's a research peptide called SS-31, used for mitochondrial function studies, prescribed by my physician.' Then hand over the prescriber letter immediately. Do not use jargon ('mitochondrial-targeted Szeto-Schiller peptide'), do not oversell the compound's benefits ('it's for heart health'), and do not mention off-label or experimental use unless the letter explicitly states it. TSA officers are trained to escalate anything that sounds evasive or overly technical. They're not evaluating the science, they're confirming you have legitimate authorization. If the officer asks to open the cooler, let them. If they ask about the vial's contents, reference the prescriber letter and offer to show the packaging label if it's from a compounding pharmacy. Most secondary inspections last 3–5 minutes and end with the officer running the vial through additional imaging or a swab test for explosives residue. Peptides don't trigger explosive detection, so the swab clears immediately.

Any temperature excursion above 8°C for more than 2–4 hours compromises SS-31's peptide structure. If your medication cooler's temperature indicator shows the vial exceeded range, the conservative answer is to discard it upon arrival and use a backup vial if you carried one. Attempting to salvage heat-exposed peptide wastes the rest of the trip. There's no home test that confirms potency after thermal denaturation. Carry a backup vial for trips longer than 48 hours or routes with known delay risk (regional connections, winter weather hubs). Store the backup separately in a second cooler or insulated sleeve. If the primary vial fails temperature control, you still have coverage. Real-world experience: travelers who carry one vial face a binary outcome (it works or it doesn't), while those carrying two vials have redundancy that eliminates the anxiety of a single point of failure.

Tarmac delays are the highest-risk event for peptide transport because cabin ventilation is reduced and temperatures can climb rapidly. If your passive cooling system was rated for 24 hours and you're three hours into a delay, you likely still have margin. But verify with your temperature logger after landing. Active cooling systems (USB refrigerators) should continue running off battery power during ground delays. If the delay exceeds your cooling system's rated duration, inform the lead flight attendant that you're transporting temperature-sensitive research material and request permission to access the aircraft's refrigeration (galleys have units maintaining 2–8°C for food service). This is a reasonable accommodation under ADA medical necessity provisions, though not guaranteed.

Do not use it. Yellow, brown, or grey discolouration indicates oxidative degradation. The peptide structure has been compromised and will not deliver consistent results. Clumpy or fluffy powder dispersed across the vial suggests incomplete lyophilisation or moisture exposure during storage. Contact the supplier immediately with photos and request a replacement with documented storage conditions. Legitimate suppliers replace degraded vials without requiring return shipping because the visual evidence is definitive.